BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 567 filers reported holding BIO-TECHNE CORP in Q4 2021. The put-call ratio across all filers is 0.60 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $19,378,236 | -16.3% | 284,681 | +0.3% | 2.64% | -9.0% |
| Q2 2023 | $23,157,860 | +10.1% | 283,693 | +0.1% | 2.90% | +5.8% |
| Q1 2023 | $21,026,336 | -3.0% | 283,412 | +8.4% | 2.74% | -7.2% |
| Q4 2022 | $21,665,827 | +27.2% | 261,412 | +335.7% | 2.95% | +25.7% |
| Q3 2022 | $17,038,000 | -15.5% | 59,992 | +3.2% | 2.35% | -8.6% |
| Q2 2022 | $20,154,000 | -19.9% | 58,142 | +0.0% | 2.57% | -9.9% |
| Q1 2022 | $25,174,000 | -16.0% | 58,133 | +0.3% | 2.85% | -5.3% |
| Q4 2021 | $29,985,000 | +9.7% | 57,959 | +2.8% | 3.01% | +4.2% |
| Q3 2021 | $27,324,000 | +17.0% | 56,388 | +8.8% | 2.89% | +3.6% |
| Q2 2021 | $23,346,000 | -2.6% | 51,850 | -17.3% | 2.79% | -2.3% |
| Q1 2021 | $23,958,000 | +17.6% | 62,730 | -2.3% | 2.86% | +9.2% |
| Q4 2020 | $20,380,000 | +30.0% | 64,179 | +1.4% | 2.62% | +12.4% |
| Q3 2020 | $15,674,000 | -14.2% | 63,269 | -8.5% | 2.33% | -13.5% |
| Q2 2020 | $18,260,000 | +10.4% | 69,149 | -20.7% | 2.69% | -18.6% |
| Q1 2020 | $16,537,000 | -8.3% | 87,209 | +6.1% | 3.30% | +17.2% |
| Q4 2019 | $18,041,000 | +11.5% | 82,189 | -0.6% | 2.82% | +3.9% |
| Q3 2019 | $16,174,000 | -1.6% | 82,659 | +4.9% | 2.71% | -1.6% |
| Q2 2019 | $16,431,000 | +5.3% | 78,809 | +0.3% | 2.76% | -0.8% |
| Q1 2019 | $15,602,000 | +37.0% | 78,579 | -0.2% | 2.78% | +20.7% |
| Q4 2018 | $11,392,000 | -31.5% | 78,719 | -3.4% | 2.30% | -13.6% |
| Q3 2018 | $16,641,000 | +2.9% | 81,529 | -25.4% | 2.67% | -8.2% |
| Q2 2018 | $16,169,000 | -10.4% | 109,289 | -8.5% | 2.90% | -11.5% |
| Q1 2018 | $18,037,000 | +31.6% | 119,419 | +12.9% | 3.28% | +27.4% |
| Q4 2017 | $13,704,000 | +6.4% | 105,782 | -0.7% | 2.57% | +1.5% |
| Q3 2017 | $12,877,000 | -15.2% | 106,517 | -17.6% | 2.54% | -18.9% |
| Q2 2017 | $15,181,000 | +3.9% | 129,202 | -10.1% | 3.13% | +2.0% |
| Q1 2017 | $14,611,000 | -25.7% | 143,734 | -24.8% | 3.07% | -8.8% |
| Q4 2016 | $19,663,000 | +9.5% | 191,214 | +16.6% | 3.36% | +14.3% |
| Q3 2016 | $17,956,000 | -4.3% | 163,979 | -1.4% | 2.94% | -7.7% |
| Q2 2016 | $18,759,000 | -15.3% | 166,344 | -29.0% | 3.19% | -8.5% |
| Q1 2016 | $22,142,000 | +12.8% | 234,255 | +7.4% | 3.48% | +6.2% |
| Q4 2015 | $19,636,000 | -1.3% | 218,174 | +1.4% | 3.28% | +1.6% |
| Q3 2015 | $19,885,000 | +10.4% | 215,071 | +17.6% | 3.23% | +25.9% |
| Q2 2015 | $18,011,000 | +28.1% | 182,913 | +30.5% | 2.56% | +22.0% |
| Q1 2015 | $14,061,000 | +118.2% | 140,199 | +101.1% | 2.10% | +111.8% |
| Q4 2014 | $6,443,000 | – | 69,730 | – | 0.99% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
| Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
| STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
| DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
| Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
| MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
| Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
| GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
| Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
| CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |